Clinical trials: Minimal Disease, Residual
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Chronic Lymphocytic Leukemia
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
This is a single-arm, open-label Phase 2 study designed to evaluate the treatment outcomes of nemtabrutinib-venetoclax-obinutuzumab as a frontline management for chronic lymphocytic leukemia (CLL).
- Trial name
- NCT07690891
- Testing
- Nemtabrutinib, Venetoclax, Obinutuzumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Leukemia, Myelodysplastic Syndromes
Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome
RATIONALE: Diagnostic procedures may improve the ability to detect residual disease. PURPOSE: Clinical trial to detect the presence of residual disease in children who are receiving therapy for acute myeloid leukemia or…
- Trial name
- NCT00003790
- Testing
- polymerase chain reaction, flow cytometry
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 496 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer
A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer who have…
- Trial name
- NCT07179315
- Testing
- cemiplimab+fianlimab, Cemiplimab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Chicago
Measurable Residual Disease
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse
A study on the Effectiveness of digital droplet PCR in monitoring measurable residual disease during the early period after allogeneic hematopoietic stem cell transplantation to predict patients at high risk of relapse
- Trial name
- NCT06000306
- Testing
- Digital Droplet PCR
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Zhejiang University
Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
The goal of this clinical trial is to learn whether the Ad5.F35-hGCC-PADRE vaccine is safe and can stimulate an immune response against gastrointestinal (GI) cancers in patients with pancreatic, colorectal, esophageal, gastric…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8
- Trial name
- NCT04111172
- Testing
- Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Thomas Jefferson University
MRD, Prostate Cancer
Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
This study is a prospective, single-center, observational study of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
- Conditions
- MRD, Prostate Cancer, mHSPC
- Trial name
- NCT07112612
- Volunteers
- 50 people
- Sponsor
- Anhui Medical University
Non-small Cell Lung Cancer, Minimal Residual Disease
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment
- Trial name
- NCT06930807
- Testing
- Adaptive postoperative management based on minimal residual disease
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking University People's Hospital
B-cell Non-Hodgkin Lymphoma, Aggressive
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin…
- Trial name
- NCT02633111
- Testing
- collected at pre-treatment tumor biopsy, Peripheral blood tests, PET/CT
- Where
- 12 sites in United States
- Volunteers
- 501 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myeloid, Acute
Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)
This retrospective multicentre cohort evaluates the agreement of measurable residual disease (MRD) detection in acute myeloid leukaemia (AML) using two flow-cytometry gating approaches.
- Trial name
- DUALFLOW (NCT07269067)
- Testing
- Conventional gating, Automated gating
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Ovarian Neoplasms, Carcinoma, Ovarian Epithelial
Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy
The purpose of this observational study is to learn if a specialized blood test can help predict whether advanced ovarian cancer will return after a patient's initial treatments are finished.
- Conditions
- Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Ovarian Cancer
- Trial name
- NCT07670962
- Testing
- Blood-based ctDNA minimal residual disease (MRD) test
- Volunteers
- 300 people
- Sponsor
- Asan Medical Center
Large-cell Lymphoma
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
This is a phase 1b clinical trial to assess the efficacy of rapcabtagene autoleucel (YTB323) administered at the recommended dose in adults with Large B Cell Lymphoma (LBCL) who are at high risk of relapse at end of first line…
- Trial name
- NCT07443137
- Testing
- Rapcabtagene autoleucel (YTB323)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Multiple Myeloma
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
This is a Phase 2 study, open-label, 2-cohort, multicenter, national, interventional in patients with newly diagnosed multiple myeloma.
- Trial name
- IFm2022-01 (NCT06353022)
- Testing
- Teclistamab, Talquetamab, Lenalidomide
- Where
- 19 sites in France
- Volunteers
- 103 people
- Sponsor
- Nantes University Hospital
Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer.
- Conditions
- Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma, Urothelial Carcinoma (UC)
- Trial name
- BLUT-DNA (NCT07756437)
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- AZ Sint-Lucas Gent
Acute Lymphoblastic Leukemia
Treatment for Ph-negative ALL for Adults up to 65 Years
The goal of this trial is to provide a protocol for treatment for adults with Ph-negative acute lymphoblastic leukemia (ALL) and to learn if this provides higher probability of survival than the previous one.
- Trial name
- LAL-2025 (NCT07443592)
- Testing
- Pediatric-type of chemotherapy (+blinatumomab for B-cell precursor ALL), Transplantation
- Where
- 95 sites in Spain
- Volunteers
- 330 people
- Sponsor
- PETHEMA Foundation
Mantle Cell Lymphoma
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
This phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete…
- Trial name
- NCT03267433
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate
- Where
- 375 sites in United States, Saudi Arabia
- Volunteers
- 689 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Adult Acute Lymphocytic Leukemia T-cell, Lymphoma, Lymphoblastic
Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath
This study tests the effectivity and tolerability of treatment with alemtuzumab (MabCampath) in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma.
- Trial name
- NCT00199030
- Testing
- Alemtuzumab (MabCampath), Cladribine
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Goethe University
Acute Lymphoblastic Leukemia
Raman Spectroscopy Compared to Flow Cytometry
The detection of MRD is associated with an increased risk of relapse and adverse prognosis in all patient groups diagnosed with acute lymphoblastic leukemia (ALL).
- Trial name
- NCT06291428
- Testing
- Raman spectroscopy
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
Multiple Myeloma
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while M-protein is a widely accepted biomarker used for multiple myeloma (MM) diagnose.
- Trial name
- NCT05536700
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization).
- Trial name
- DRAMMATIC (NCT04071457)
- Testing
- Lenalidomide, Daratumumab/rHuPH20
- Where
- 842 sites in United States, Canada
- Volunteers
- 1,100 people
- Sponsor
- SWOG Cancer Research Network